ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2024
Leveraging Large Language Models for Cancer Vaccine Adjuvant Name Extraction from Biomedical Literature.
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vaxjo 2.0: An ontology- and large language model-powered knowledge base of vaccine adjuvants and mechanisms.Frontiers in cellular and infection microbiology · 2026Article
- Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
This study explores cancer vaccine adjuvant name recognition using Large Language Models (LLMs), specifically Generative Pretrained Transformers (GPT), Large Language Model Meta AI (Llama), and Gemma. The models were tested in zero- and few-shot learning paradigms using AdjuvareDB and Vaccine Adjuvant Compendium (VAC) datasets. Prompts were designed to extract adjuvant names and assess the impact of contextual details. Notably, Llama-3.2 3B achieved a Recall of up to 68.7% (72.5% with manual validation) on the VAC dataset with four-shots, although its Precision and F1-score were lower. In contrast, GPT-4o, with additional contextual interventions, achieved a Precision of 65.9%, Recall of 79.7%, and F1-score of 69.8% on the AdjuvareDB dataset. Gemma-2 9B also demonstrated moderate few-shot gains, peaking at 63.6% F1-score. These LLMs outperformed BioBERT, a model widely used for biomedical text mining, highlighting the potential of general-purpose LLMs for automatic vaccine adjuvant name extraction and contributing to advancements in vaccine research.
Indexed as
Identifiers
41726492PMC12919462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.